Back to Dashboard
HRTX · Healthcare

Heron Therapeutics, Inc.

USA Healthcare
Market cap
$55M
Industry
Biotechnology
Sector
Healthcare
Exchange
NasdaqCM
About Heron Therapeutics, Inc.

Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and…

Congressional trades · 1 on record
Disclosures from 2021-03-31 to 2021-03-31
The newest disclosure we hold for this stock is 2021-03-31. That is the end of our data, not necessarily the end of the trading — our bulk STOCK Act archive stops there and newer filings arrive through a separate live feed. Treat the absence of recent rows as “not covered”, not as “no trades”.
Trade date Member Chamber Action Amount
2021-03-31 Ashley Hinson · R-IA House Sold $1,001 - $15,000
Not in our coverage. Heron Therapeutics, Inc. isn't currently held by any of the 50 hedge funds we track. The price chart and company profile below come from public Yahoo Finance data.
Price History
Loading price data...
A member of Congress bought A member sold
Return: High: Low:

Markers sit on the transaction date the member disclosed, snapped to the nearest close on the chart. They are not the date the public found out — that came later, and the gap is its own page. Every marker is listed by name in the table above.

⚠ Disclaimer: This page is for informational purposes only. Holdings data from SEC EDGAR 13F filings, delayed up to 135 days. Not a recommendation to buy or sell Heron Therapeutics, Inc. or any security.

Get the Weekly Update

Every week, we'll send you what Buffett, Dalio, Ackman and 47 other legendary investors are buying — free, straight from their SEC filings.
Free forever · No spam · Unsubscribe anytime